{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "NCT02728115",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "InterventionArmGroupLabel",
                  "InterventionBrowseBranchAbbrev",
                  "InterventionBrowseBranchName",
                  "InterventionBrowseLeafAsFound",
                  "InterventionBrowseLeafId",
                  "InterventionBrowseLeafName",
                  "InterventionBrowseLeafRelevance",
                  "InterventionDescription",
                  "InterventionMeshId",
                  "InterventionMeshTerm",
                  "InterventionName",
                  "InterventionOtherName",
                  "InterventionType",
                  "IsFDARegulatedDevice",
                  "IsFDARegulatedDrug",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "InterventionArmGroupLabel": [
                              "Cellavita HD Lower Dose",
                              "Cellavita HD Higher dose"
                        ],
                        "InterventionBrowseBranchAbbrev": [],
                        "InterventionBrowseBranchName": [],
                        "InterventionBrowseLeafAsFound": [],
                        "InterventionBrowseLeafId": [],
                        "InterventionBrowseLeafName": [],
                        "InterventionBrowseLeafRelevance": [],
                        "InterventionDescription": [
                              "The first three participants enrolled in the study will be assigned to the lower dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.",
                              "The last three participants enrolled in the study will be assigned to the higher dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days."
                        ],
                        "InterventionMeshId": [],
                        "InterventionMeshTerm": [],
                        "InterventionName": [
                              "Cellavita HD Lower Dose",
                              "Cellavita HD Higher dose"
                        ],
                        "InterventionOtherName": [
                              "cellular therapy, mesenchymal stem cells",
                              "cellular therapy, mesenchymal stem cells"
                        ],
                        "InterventionType": [
                              "Biological",
                              "Biological"
                        ],
                        "IsFDARegulatedDevice": [
                              "No"
                        ],
                        "IsFDARegulatedDrug": [
                              "No"
                        ],
                        "NCTId": [
                              "NCT02728115"
                        ]
                  }
            ]
      }
}